US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 2019-2025

The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per 100,000 population respectively in 2015. Moreover, the CDC also estimates the incidence rate of types of IBD across the country. As per the CDC, the incidence of Crohn’s disease and ulcerative colitis were nearly 14.6 and 14.3 per 100,000 population respectively in 2015. Additionally, according to the aforementioned organization, the percentage of people diagnosed with IBD (either Crohn’s disease or ulcerative colitis) increased from 0.9% of US adults in 1999 to 1.3% of US adults in 2015. This percentage is further expected to expand in the near future; thereby, promising significant growth for the IBD market during the forecast period.

A full report of US Inflammatory Bowel Disease (IBD) Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/us-ibd-inflammatory-bowel-disease-therapeutics-market

US IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/us-ibd-inflammatory-bowel-disease-therapeutics-market

The companies which are contributing to the growth of the US IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

US Inflammatory Bowel Disease (IBD) Therapeutics Market- Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease

By Treatment Type

• Surgery
• Anti- Inflammatory Drug Administration

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/us-ibd-inflammatory-bowel-disease-therapeutics-market

Company Profiles

• Abbott Laboratories
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Celgene Corp.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Sanofi S.A.
• Takeda pharmaceutical Co., Ltd.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

This release was published on openPR.